Federal contract award
36C26023P0532
RADIOPHARMACEUTICAL ISOTOPES
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Veterans Affairs |
| Office | 260-NETWORK CONTRACT OFFICE 20 (36C260) |
| NAICS | 325412 — Pharmaceutical Preparation Manufacturing |
| PSC | 6505 — Drugs and Biologicals |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $337.1K |
| Current contract value | $337.1K |
| Potential contract value / ceiling | $1.0M |
| Start date | Jun 1, 2023 |
| Current end date | Nov 30, 2026 |
| Potential end date | Nov 30, 2027 |
| Latest award activity | Jun 9, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 13 of 13 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jun 9, 2026 | A14398 | $0 | IMPLEMENTING EO 14398 DEI DISCRIMINATION SPOKANE VA MEDICAL CENTER- RADIOPHARMACEUTICAL DRUGS, OPTION YEAR TWO (3), 52.217-9 OPTION TO EXTEND THE TERM OF THE CONTRACT. |
| May 19, 2026 | P00011 | $-68.5K | SPOKANE VA MEDICAL CENTER- RADIOPHARMACEUTICAL DRUGS, OPTION YEAR TWO (3), 52.217-9 OPTION TO EXTEND THE TERM OF THE CONTRACT. |
| Feb 24, 2026 | P00009 | $0 | SPOKANE VA MEDICAL CENTER- RADIOPHARMACEUTICAL DRUGS, OPTION YEAR TWO (3), 52.217-9 OPTION TO EXTEND THE TERM OF THE CONTRACT. |
| Dec 31, 2025 | P00010 | $5.1K | SPOKANE VA MEDICAL CENTER- RADIOPHARMACEUTICAL DRUGS, OPTION YEAR TWO (3),CLIN ADD FOR PHAMRA DRUG TEST ANALYSIS MONTHLY (11 MONTHS). |
| Nov 12, 2025 | P00008 | $221.2K | SPOKANE VA MEDICAL CENTER- RADIOPHARMACEUTICAL DRUGS, OPTION YEAR TWO (3), 52.217-9 OPTION TO EXTEND THE TERM OF THE CONTRACT. |
| Jul 30, 2025 | P00007 | $-3 | SPOKANE VA MEDICAL CENTER- RADIOPHARMACEUTICAL DRUGS, ADMIN MOD OF PURCHASE ORDER NUMBER AND SUMMARY TOTAL PRICING. |
| Jul 25, 2025 | P00006 | $-5.6K | SPOKANE VA MEDICAL CENTER- RADIOPHARMACEUTICAL DRUGS, OPTION YEARS 2-4, CLIN DECREASES, CLIN ADDS, CLIN INCREASES FAR 52.212-4 (C) |
| May 2, 2025 | P00005 | $-63.6K | SPOKANE VA MEDICAL CENTER- RADIOPHARMACEUTICAL DRUGS, OPTION YEAR TWO (2), 52.217-9 OPTION TO EXTEND THE TERM OF THE CONTRACT. |
| Nov 25, 2024 | P00004 | $216.4K | SPOKANE VA MEDICAL CENTER- RADIOPHARMACEUTICAL DRUGS, OPTION YEAR TWO (2), 52.217-9 OPTION TO EXTEND THE TERM OF THE CONTRACT. |
| Aug 27, 2024 | P00003 | $-329.5K | MOD CLIN CHANGES RADIOPHARMACEUTICAL ISOTOPES |
| Aug 19, 2024 | P00002 | $-201.1K | RADIOPHARMACEUTICAL ISOTOPES |
| Oct 31, 2023 | P00001 | $285.5K | RADIOPHARMACEUTICAL ISOTOPES |
| May 31, 2023 | 0 | $277.3K | RADIOPHARMACEUTICAL ISOTOPES |
Estimated positioning window
Nov 30, 2026 – May 30, 2027
70/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 70/100. Available recorded signals: 65 points.
- Contract end 2027-11-30 (394 days from calculation)
- +25 points
- 231 historical awards in this buyer and category group
- +15 points
- 13 recorded award transactions
- +10 points
- Latest award action: 2026-06-09
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.